Ruiliang Wang

301 Middle Yan Chang Road
Shanghai, 200072, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Correction: M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2 transcription.

Correction: M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2 transcription.

Journal: Oncogene

Published: September 17, 2025

Pseudomonas aeruginosa Exacerbates Bladder Cancer Progression by Activating Cancer-Driven Immunosuppression.

Pseudomonas aeruginosa Exacerbates Bladder Cancer Progression by Activating Cancer-Driven Immunosuppression.

Journal: Cancer immunology research

Published: July 16, 2025

Pseudomonas aeruginosa exacerbates bladder cancer progression by activating cancer-driven immunosuppression.

Pseudomonas aeruginosa exacerbates bladder cancer progression by activating cancer-driven immunosuppression.

Journal: Cancer immunology research

Published: July 16, 2025

Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.

Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.

Journal: Cancer research communications

Published: July 12, 2025

Risk of subsequent primary cancers in bladder cancer survivors.

Risk of subsequent primary cancers in bladder cancer survivors.

Journal: Clinical and experimental medicine

Published: June 17, 2024

Acetyltransferase NAT10 promotes an immunosuppressive microenvironment by modulating CD8+ T cell activity in prostate cancer.

Acetyltransferase NAT10 promotes an immunosuppressive microenvironment by modulating CD8+ T cell activity in prostate cancer.

Journal: Molecular biomedicine

Published: April 26, 2024

De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy: Network-analysis and systematic review.

De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy: Network-analysis and systematic review.

Journal: Chinese medical journal

Published: April 08, 2024

Can uric acid affect the immune microenvironment in bladder cancer? A single-center multi-omics study.

Can uric acid affect the immune microenvironment in bladder cancer? A single-center multi-omics study.

Journal: Molecular carcinogenesis

Published: September 21, 2023

Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer.

Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer.

Journal: iScience

Published: July 31, 2023

Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer.

Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer.

Journal: Cancer research communications

Published: July 02, 2023

Corrigendum: MicroRNA-153 decreases tryptophan catabolism and inhibits angiogenesis in bladder cancer by targeting indoleamine 2,3-dioxygenase 1.

Corrigendum: MicroRNA-153 decreases tryptophan catabolism and inhibits angiogenesis in bladder cancer by targeting indoleamine 2,3-dioxygenase 1.

Journal: Frontiers in oncology

Published: April 19, 2023

M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2 transcription.

M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2 transcription.

Journal: Oncogene

Published: April 08, 2023

Showing 1-12 of 46

Last Updated: 09/26/2026